Cargando…
CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283527/ https://www.ncbi.nlm.nih.gov/pubmed/35835736 http://dx.doi.org/10.1038/s41392-022-01030-x |
| _version_ | 1784747332072374272 |
|---|---|
| author | Liu, Mingyue Wang, Xu Du, Xuexiang Zhang, Yan Ai, Chunxia Hu-Lieskovan, Siwen Li, Tianhong Devenport, Martin Liu, Yang Zheng, Pan |
| author_facet | Liu, Mingyue Wang, Xu Du, Xuexiang Zhang, Yan Ai, Chunxia Hu-Lieskovan, Siwen Li, Tianhong Devenport, Martin Liu, Yang Zheng, Pan |
| author_sort | Liu, Mingyue |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9283527 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92835272022-07-16 CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect Liu, Mingyue Wang, Xu Du, Xuexiang Zhang, Yan Ai, Chunxia Hu-Lieskovan, Siwen Li, Tianhong Devenport, Martin Liu, Yang Zheng, Pan Signal Transduct Target Ther Letter Nature Publishing Group UK 2022-07-15 /pmc/articles/PMC9283527/ /pubmed/35835736 http://dx.doi.org/10.1038/s41392-022-01030-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Liu, Mingyue Wang, Xu Du, Xuexiang Zhang, Yan Ai, Chunxia Hu-Lieskovan, Siwen Li, Tianhong Devenport, Martin Liu, Yang Zheng, Pan CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| title | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| title_full | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| title_fullStr | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| title_full_unstemmed | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| title_short | CD24Fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| title_sort | cd24fc ameliorates immune-related adverse events while preserving anti-tumor therapeutic effect |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283527/ https://www.ncbi.nlm.nih.gov/pubmed/35835736 http://dx.doi.org/10.1038/s41392-022-01030-x |
| work_keys_str_mv | AT liumingyue cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT wangxu cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT duxuexiang cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT zhangyan cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT aichunxia cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT hulieskovansiwen cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT litianhong cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT devenportmartin cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT liuyang cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect AT zhengpan cd24fcamelioratesimmunerelatedadverseeventswhilepreservingantitumortherapeuticeffect |